Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and SHR-1210 in Advanced HCC or Gastric Cancer
NCT02942329Phase 2Unknown
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), gastric cancer (GC), sponsored by 307 Hospital of the People's Liberation Army. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT02942329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942329.